# References

> References — Research Peptide Fundamentals research peptides — Peptide Online Digest — The full citation list behind this digest of Research Peptide Fundamentals research peptides: seventeen sources on BPC-157, ipamorelin and tirzepatide, with identifiers and links where available.

**RESEARCH PEPTIDE FUNDAMENTALS / SOURCES**

Every source cited across the three compound pages, the comparison and the questions, gathered in one numbered list.

## The source list

Seventeen sources support this site: five on BPC-157, seven on ipamorelin and five on tirzepatide. Each is listed once and referred to by its number wherever it is used. Where an entry is a review or a clinical-reference chapter rather than a primary trial, the text that cites it says so.

One pattern is visible in the list itself and is worth naming: the tirzepatide entries are large controlled human trials, the BPC-157 entries are mostly animal work plus a two-person pilot, and the ipamorelin entries include one failed trial and a safety study of a different molecule. The shape of a reference list is itself a finding.

## References

[1] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40131143/
[2] McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[3] He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. https://pubmed.ncbi.nlm.nih.gov/36588717/
[4] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[5] Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10:1032-1037. https://pubmed.ncbi.nlm.nih.gov/15052688/
[6] Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW, Giuliano C, Lovati E, Pietra C, Rudd JA. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & Behavior. 2024;284:114644. https://pubmed.ncbi.nlm.nih.gov/39043357/
[7] Stokes AH, Falls JG, Yoon L, Cariello N, Faiola B, Colton HM, Jordan HL, Berridge BR. Integrated approach to early detection of cardiovascular toxicity induced by a ghrelin receptor agonist. International Journal of Toxicology. 2015;34(2):151-161. https://pubmed.ncbi.nlm.nih.gov/25722321/
[8] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29(12):1527-1534. https://pubmed.ncbi.nlm.nih.gov/25331030/
[9] Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. https://pubmed.ncbi.nlm.nih.gov/10496658/
[10] Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113. https://pubmed.ncbi.nlm.nih.gov/10373343/
[11] Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/
[12] Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine. 2026;54:223-229. https://doi.org/10.1177/03635465251357593
[13] Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40353578/
[14] Farzam K, Patel P. Tirzepatide (StatPearls). StatPearls [Internet], NCBI Bookshelf. 2024. https://www.ncbi.nlm.nih.gov/books/NBK585056/
[15] Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023. https://pubmed.ncbi.nlm.nih.gov/37908750/
[16] Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/
[17] Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/34170647/

---

Peptide Online Digest is a reading desk that examines three peptide literatures for what they cannot establish about the material itself — it sells nothing, stocks nothing, prescribes nothing, and points to no route for obtaining any compound.